PROCEEDINGS VOLUME 2392
PHOTONICS WEST '95 | 1-28 FEBRUARY 1995
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IV
IN THIS VOLUME

0 Sessions, 21 Papers, 0 Presentations
Pre-Clinical  (6)
Mechanisms  (6)
PHOTONICS WEST '95
1-28 February 1995
San Jose, CA, United States
Pre-Clinical
Proc. SPIE 2392, Uptake of the photosensitizer tin ethyl etiopupurin by the canine prostate and its tissue effects when combined with red light, 0000 (1 May 1995); doi: 10.1117/12.208171
Proc. SPIE 2392, Kinetics of ALA-induced protoporphyrin IX accumulation in the liver, skin, and tumor of a rat model, 0000 (1 May 1995); doi: 10.1117/12.208188
Proc. SPIE 2392, Improved efficacy of SnET2 mediated PDT with the simultaneous application of selective hyperthermia, 0000 (1 May 1995); doi: 10.1117/12.208189
Proc. SPIE 2392, Effect of photodynamic therapy using benzoporphyrin derivative on the cutaneous immune response, 0000 (1 May 1995); doi: 10.1117/12.208190
Clinical/Detection
Proc. SPIE 2392, Phosphorescent detection of a hyperoxia and hypoxia in tumors during photodynamic action, 0000 (1 May 1995); doi: 10.1117/12.208191
Pre-Clinical
Proc. SPIE 2392, Hyperglycemia enhances the effectiveness of PDT, 0000 (1 May 1995); doi: 10.1117/12.208172
Clinical/Detection
Proc. SPIE 2392, Endoscopic frequency-domain fluorescence lifetime imaging for clinical cancer photodetection: apparatus design, 0000 (1 May 1995); doi: 10.1117/12.208173
Proc. SPIE 2392, Diode laser systems for photodynamic therapy, 0000 (1 May 1995); doi: 10.1117/12.208174
Proc. SPIE 2392, Light emitting diode (LED) system for photodynamic therapy, 0000 (1 May 1995); doi: 10.1117/12.208175
Proc. SPIE 2392, Quantitative fluorescence microscopy yields distributions of concentration and photobleaching rate in 5ALA-induced protoporphyrin IX in cell population, 0000 (1 May 1995); doi: 10.1117/12.208176
Proc. SPIE 2392, Tissue dependent biosynthesis and pharmacokinetics of Protopophyrin IX following intravenous injection of <delta>-aminolevulinic acid, 0000 (1 May 1995); doi: 10.1117/12.208177
Proc. SPIE 2392, Our experience of PDT of cancer with two Russian-produced photosensitizers, 0000 (1 May 1995); doi: 10.1117/12.208178
Proc. SPIE 2392, Differences of photodamage in various malignant tissues which appear after application of photodynamic therapy using different laser systems, 0000 (1 May 1995); doi: 10.1117/12.208179
Mechanisms
Proc. SPIE 2392, Mechanisms of phototoxicity catalyzed by two porphycenes, 0000 (1 May 1995); doi: 10.1117/12.208180
Proc. SPIE 2392, Distinctive role of activated tumor-associated macrophages in photosensitizer accumulation, 0000 (1 May 1995); doi: 10.1117/12.208181
Proc. SPIE 2392, Importance of fluence rate in photodynamic therapy with ALA-induced PpIX and BPD-MA in a rat bladder tumor model, 0000 (1 May 1995); doi: 10.1117/12.208182
Proc. SPIE 2392, Oxygen sensitivity of PDT determined from time-dependent electrode measurements in spheroids, 0000 (1 May 1995); doi: 10.1117/12.208183
Clinical/Detection
Proc. SPIE 2392, Photodynamic therapy and the treatment of malignancies of the head and neck, 0000 (1 May 1995); doi: 10.1117/12.208184
Mechanisms
Proc. SPIE 2392, ALA-mediated PDT of melanoma tumors: light-sensitizer interactions determined by a novel spectral imaging system, 0000 (1 May 1995); doi: 10.1117/12.208185
Pre-Clinical
Proc. SPIE 2392, Compact sealed-off gold vapor laser for photodynamic therapy, 0000 (1 May 1995); doi: 10.1117/12.208186
Mechanisms
Proc. SPIE 2392, Photodynamic therapy for endometrial ablation: a study of treatment parameters and effects, 0000 (1 May 1995); doi: 10.1117/12.208187
Back to Top